Global Liposome Drug Delivery Market research

Liposome Drug Delivery Comprehensive Study by Type (Liposomal Doxorubicin, Liposomal Amphotericin B, Liposomal Paclitaxel), Application (Pharmaceutical, Cosmetic, Food, Farming), Therapy (Fungal Infection Therapy, Cancer & Tumor Therapy, Others) Players and Region - Global Market Outlook to 2030

Liposome Drug Delivery Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 14.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Liposomes is defined as the small spherical-shaped artificial vesicles, which are synthesized from phospholipids and cholesterol. It is colloidal carriers as well as a range from 0.01 to 5.0 μm in diameter. It is widely used to improve the therapeutic index of established drugs by reducing metabolism and reducing toxicity. New applications for the delivery of new biotechnology products, for instance, recombinant proteins antisense oligonucleotides, as well as cloned genes, are some of the major drivers which are propelling the growth of the market. According to AMA Research, the market for Liposome Drug Delivery is expected to register a CAGR of 14.8% during the forecast period to 2030. This growth is primarily driven by Rising Prevalence of Chronic Diseases .

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Pharmaceuticals sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Gilead Sciences, Inc., (United States), Pacira (United States), Sun Pharmaceutical (India), Luye Pharma (China), Sigma-Tau Group (Switzerland), Fudan-Zhangjiang (China), Teva Pharmaceutical Industries Ltd. (Israel), CSPC (United States), Novartis International AG (Switzerland) and Kingond Pharm (China), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In January 2022, Sun Pharma Advanced Research Company was manufacturing a liposome-encapsulated formulation of the taxane compound paclitaxel (a tubulin inhibitor) for the treatment of breast cancer.
In June 2022, Endo International plc's subsidiary Endo Ventures Limited (EVL) entered into an agreement with Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical company, to commercialize TLC599, a TLC investigational product. TLC599 is an injectable compound in phase 3 development for the treatment of osteoarthritis knee pain.The market is fragmented with numerous players focusing on technique and quality of the product due to which the global liposome drug delivery market can witness an upsurge in the forecast period.

Regulatory Insights:
On August 2018, the United States Food and Drug Administration (FDA), has published its final guidance for industry on liposome drug products in April 2018. In addition, it finalizes the revised draft guidance for industry Liposome Drug Products

Influencing Trend:
Rapid Advancements in targeted Drug Delivery Systems

Market Growth Drivers:
Rising Prevalence of Chronic Diseases, Technological Advancements and New Product Launches and Growth in the Biologics Market

Challenges:
Problem related to Pricing Pressure

Restraints:
The problem regarding the Low Solubility, Short Half-Life, and High Production Cost are the Restraints of the Market in future

Opportunities:
Rising Demand from Emerging Economics such as India, China and others and Rising Demand for Biosimilars and Self-Administration and Home Care

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Liposome Drug Delivery Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Liposome Drug Delivery Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Liposome Drug Delivery players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Liposome Drug Delivery Study Sheds Light on
— The Liposome Drug Delivery Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Liposome Drug Delivery industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Liposome Drug Delivery industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Liposomal Doxorubicin
  • Liposomal Amphotericin B
  • Liposomal Paclitaxel
By Application
  • Pharmaceutical
  • Cosmetic
  • Food
  • Farming
By Therapy
  • Fungal Infection Therapy
  • Cancer & Tumor Therapy
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Chronic Diseases
      • 3.2.2. Technological Advancements and New Product Launches
      • 3.2.3. Growth in the Biologics Market
    • 3.3. Market Challenges
      • 3.3.1. Problem related to Pricing Pressure
    • 3.4. Market Trends
      • 3.4.1. Rapid Advancements in targeted Drug Delivery Systems
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Liposome Drug Delivery, by Type, Application, Therapy and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Liposome Drug Delivery (Value)
      • 5.2.1. Global Liposome Drug Delivery by: Type (Value)
        • 5.2.1.1. Liposomal Doxorubicin
        • 5.2.1.2. Liposomal Amphotericin B
        • 5.2.1.3. Liposomal Paclitaxel
      • 5.2.2. Global Liposome Drug Delivery by: Application (Value)
        • 5.2.2.1. Pharmaceutical
        • 5.2.2.2. Cosmetic
        • 5.2.2.3. Food
        • 5.2.2.4. Farming
      • 5.2.3. Global Liposome Drug Delivery by: Therapy (Value)
        • 5.2.3.1. Fungal Infection Therapy
        • 5.2.3.2. Cancer & Tumor Therapy
        • 5.2.3.3. Others
      • 5.2.4. Global Liposome Drug Delivery Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Liposome Drug Delivery: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Gilead Sciences, Inc., (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pacira (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sun Pharmaceutical (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Luye Pharma (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sigma-Tau Group (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Fudan-Zhangjiang (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. CSPC (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis International AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Kingond Pharm (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Liposome Drug Delivery Sale, by Type, Application, Therapy and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Liposome Drug Delivery (Value)
      • 7.2.1. Global Liposome Drug Delivery by: Type (Value)
        • 7.2.1.1. Liposomal Doxorubicin
        • 7.2.1.2. Liposomal Amphotericin B
        • 7.2.1.3. Liposomal Paclitaxel
      • 7.2.2. Global Liposome Drug Delivery by: Application (Value)
        • 7.2.2.1. Pharmaceutical
        • 7.2.2.2. Cosmetic
        • 7.2.2.3. Food
        • 7.2.2.4. Farming
      • 7.2.3. Global Liposome Drug Delivery by: Therapy (Value)
        • 7.2.3.1. Fungal Infection Therapy
        • 7.2.3.2. Cancer & Tumor Therapy
        • 7.2.3.3. Others
      • 7.2.4. Global Liposome Drug Delivery Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Liposome Drug Delivery: by Type(USD Million)
  • Table 2. Liposome Drug Delivery Liposomal Doxorubicin , by Region USD Million (2018-2023)
  • Table 3. Liposome Drug Delivery Liposomal Amphotericin B , by Region USD Million (2018-2023)
  • Table 4. Liposome Drug Delivery Liposomal Paclitaxel , by Region USD Million (2018-2023)
  • Table 5. Liposome Drug Delivery: by Application(USD Million)
  • Table 6. Liposome Drug Delivery Pharmaceutical , by Region USD Million (2018-2023)
  • Table 7. Liposome Drug Delivery Cosmetic , by Region USD Million (2018-2023)
  • Table 8. Liposome Drug Delivery Food , by Region USD Million (2018-2023)
  • Table 9. Liposome Drug Delivery Farming , by Region USD Million (2018-2023)
  • Table 10. Liposome Drug Delivery: by Therapy(USD Million)
  • Table 11. Liposome Drug Delivery Fungal Infection Therapy , by Region USD Million (2018-2023)
  • Table 12. Liposome Drug Delivery Cancer & Tumor Therapy , by Region USD Million (2018-2023)
  • Table 13. Liposome Drug Delivery Others , by Region USD Million (2018-2023)
  • Table 14. South America Liposome Drug Delivery, by Country USD Million (2018-2023)
  • Table 15. South America Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 16. South America Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 17. South America Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 18. Brazil Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 19. Brazil Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 20. Brazil Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 21. Argentina Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 22. Argentina Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 23. Argentina Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 24. Rest of South America Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 27. Asia Pacific Liposome Drug Delivery, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 31. China Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 32. China Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 33. China Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 34. Japan Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 35. Japan Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 36. Japan Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 37. India Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 38. India Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 39. India Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 40. South Korea Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 41. South Korea Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 42. South Korea Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 43. Taiwan Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 44. Taiwan Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 45. Taiwan Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 46. Australia Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 47. Australia Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 48. Australia Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 52. Europe Liposome Drug Delivery, by Country USD Million (2018-2023)
  • Table 53. Europe Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 54. Europe Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 55. Europe Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 56. Germany Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 57. Germany Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 58. Germany Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 59. France Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 60. France Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 61. France Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 62. Italy Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 63. Italy Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 64. Italy Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 65. United Kingdom Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 68. Netherlands Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 69. Netherlands Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 70. Netherlands Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 71. Rest of Europe Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 74. MEA Liposome Drug Delivery, by Country USD Million (2018-2023)
  • Table 75. MEA Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 76. MEA Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 77. MEA Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 78. Middle East Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 79. Middle East Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 80. Middle East Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 81. Africa Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 82. Africa Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 83. Africa Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 84. North America Liposome Drug Delivery, by Country USD Million (2018-2023)
  • Table 85. North America Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 86. North America Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 87. North America Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 88. United States Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 89. United States Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 90. United States Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 91. Canada Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 92. Canada Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 93. Canada Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 94. Mexico Liposome Drug Delivery, by Type USD Million (2018-2023)
  • Table 95. Mexico Liposome Drug Delivery, by Application USD Million (2018-2023)
  • Table 96. Mexico Liposome Drug Delivery, by Therapy USD Million (2018-2023)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Liposome Drug Delivery: by Type(USD Million)
  • Table 108. Liposome Drug Delivery Liposomal Doxorubicin , by Region USD Million (2025-2030)
  • Table 109. Liposome Drug Delivery Liposomal Amphotericin B , by Region USD Million (2025-2030)
  • Table 110. Liposome Drug Delivery Liposomal Paclitaxel , by Region USD Million (2025-2030)
  • Table 111. Liposome Drug Delivery: by Application(USD Million)
  • Table 112. Liposome Drug Delivery Pharmaceutical , by Region USD Million (2025-2030)
  • Table 113. Liposome Drug Delivery Cosmetic , by Region USD Million (2025-2030)
  • Table 114. Liposome Drug Delivery Food , by Region USD Million (2025-2030)
  • Table 115. Liposome Drug Delivery Farming , by Region USD Million (2025-2030)
  • Table 116. Liposome Drug Delivery: by Therapy(USD Million)
  • Table 117. Liposome Drug Delivery Fungal Infection Therapy , by Region USD Million (2025-2030)
  • Table 118. Liposome Drug Delivery Cancer & Tumor Therapy , by Region USD Million (2025-2030)
  • Table 119. Liposome Drug Delivery Others , by Region USD Million (2025-2030)
  • Table 120. South America Liposome Drug Delivery, by Country USD Million (2025-2030)
  • Table 121. South America Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 122. South America Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 123. South America Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 124. Brazil Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 125. Brazil Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 126. Brazil Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 127. Argentina Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 128. Argentina Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 129. Argentina Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 130. Rest of South America Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 131. Rest of South America Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 132. Rest of South America Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 133. Asia Pacific Liposome Drug Delivery, by Country USD Million (2025-2030)
  • Table 134. Asia Pacific Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 135. Asia Pacific Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 136. Asia Pacific Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 137. China Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 138. China Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 139. China Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 140. Japan Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 141. Japan Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 142. Japan Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 143. India Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 144. India Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 145. India Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 146. South Korea Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 147. South Korea Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 148. South Korea Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 149. Taiwan Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 150. Taiwan Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 151. Taiwan Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 152. Australia Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 153. Australia Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 154. Australia Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 155. Rest of Asia-Pacific Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 158. Europe Liposome Drug Delivery, by Country USD Million (2025-2030)
  • Table 159. Europe Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 160. Europe Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 161. Europe Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 162. Germany Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 163. Germany Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 164. Germany Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 165. France Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 166. France Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 167. France Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 168. Italy Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 169. Italy Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 170. Italy Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 171. United Kingdom Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 172. United Kingdom Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 173. United Kingdom Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 174. Netherlands Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 175. Netherlands Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 176. Netherlands Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 177. Rest of Europe Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 178. Rest of Europe Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 179. Rest of Europe Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 180. MEA Liposome Drug Delivery, by Country USD Million (2025-2030)
  • Table 181. MEA Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 182. MEA Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 183. MEA Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 184. Middle East Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 185. Middle East Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 186. Middle East Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 187. Africa Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 188. Africa Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 189. Africa Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 190. North America Liposome Drug Delivery, by Country USD Million (2025-2030)
  • Table 191. North America Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 192. North America Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 193. North America Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 194. United States Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 195. United States Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 196. United States Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 197. Canada Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 198. Canada Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 199. Canada Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 200. Mexico Liposome Drug Delivery, by Type USD Million (2025-2030)
  • Table 201. Mexico Liposome Drug Delivery, by Application USD Million (2025-2030)
  • Table 202. Mexico Liposome Drug Delivery, by Therapy USD Million (2025-2030)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Liposome Drug Delivery: by Type USD Million (2018-2023)
  • Figure 5. Global Liposome Drug Delivery: by Application USD Million (2018-2023)
  • Figure 6. Global Liposome Drug Delivery: by Therapy USD Million (2018-2023)
  • Figure 7. South America Liposome Drug Delivery Share (%), by Country
  • Figure 8. Asia Pacific Liposome Drug Delivery Share (%), by Country
  • Figure 9. Europe Liposome Drug Delivery Share (%), by Country
  • Figure 10. MEA Liposome Drug Delivery Share (%), by Country
  • Figure 11. North America Liposome Drug Delivery Share (%), by Country
  • Figure 12. Global Liposome Drug Delivery share by Players 2023 (%)
  • Figure 13. Global Liposome Drug Delivery share by Players (Top 3) 2023(%)
  • Figure 14. Global Liposome Drug Delivery share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Gilead Sciences, Inc., (United States) Revenue, Net Income and Gross profit
  • Figure 17. Gilead Sciences, Inc., (United States) Revenue: by Geography 2023
  • Figure 18. Pacira (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pacira (United States) Revenue: by Geography 2023
  • Figure 20. Sun Pharmaceutical (India) Revenue, Net Income and Gross profit
  • Figure 21. Sun Pharmaceutical (India) Revenue: by Geography 2023
  • Figure 22. Luye Pharma (China) Revenue, Net Income and Gross profit
  • Figure 23. Luye Pharma (China) Revenue: by Geography 2023
  • Figure 24. Sigma-Tau Group (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Sigma-Tau Group (Switzerland) Revenue: by Geography 2023
  • Figure 26. Fudan-Zhangjiang (China) Revenue, Net Income and Gross profit
  • Figure 27. Fudan-Zhangjiang (China) Revenue: by Geography 2023
  • Figure 28. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 29. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 30. CSPC (United States) Revenue, Net Income and Gross profit
  • Figure 31. CSPC (United States) Revenue: by Geography 2023
  • Figure 32. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 34. Kingond Pharm (China) Revenue, Net Income and Gross profit
  • Figure 35. Kingond Pharm (China) Revenue: by Geography 2023
  • Figure 36. Global Liposome Drug Delivery: by Type USD Million (2025-2030)
  • Figure 37. Global Liposome Drug Delivery: by Application USD Million (2025-2030)
  • Figure 38. Global Liposome Drug Delivery: by Therapy USD Million (2025-2030)
  • Figure 39. South America Liposome Drug Delivery Share (%), by Country
  • Figure 40. Asia Pacific Liposome Drug Delivery Share (%), by Country
  • Figure 41. Europe Liposome Drug Delivery Share (%), by Country
  • Figure 42. MEA Liposome Drug Delivery Share (%), by Country
  • Figure 43. North America Liposome Drug Delivery Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Gilead Sciences, Inc., (United States)
  • Pacira (United States)
  • Sun Pharmaceutical (India)
  • Luye Pharma (China)
  • Sigma-Tau Group (Switzerland)
  • Fudan-Zhangjiang (China)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • CSPC (United States)
  • Novartis International AG (Switzerland)
  • Kingond Pharm (China)
Additional players considered in the study are as follows:
Spectrum Pharmaceuticals (United States) , Shanghai New Asia (china)
Select User Access Type

Key Highlights of Report


Apr 2024 248 Pages 58 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Liposome Drug Delivery Market research Quantitative research analysis
Global Liposome Drug Delivery Market research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2023; Base year: 2023; Forecast period: 2024 to 2030
Companies that are profiled in Global Liposome Drug Delivery Market are Gilead Sciences, Inc., (United States), Pacira (United States), Sun Pharmaceutical (India), Luye Pharma (China), Sigma-Tau Group (Switzerland), Fudan-Zhangjiang (China), Teva Pharmaceutical Industries Ltd. (Israel), CSPC (United States), Novartis International AG (Switzerland) and Kingond Pharm (China) etc.
Pharmaceutical segment in Global market to hold robust market share owing to "Rising Prevalence of Chronic Diseases ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Liposome Drug Delivery market throughout the forecasted period.

Know More About Global Liposome Drug Delivery Market research Report?

Have a Query? Click Here

Other Related Reports

Anti-infective Agents Comprehensive Study by Type (Antibacterial Drugs, Antifungal Drugs, Antiviral Drugs), Application (Hospital Use, Clinic Use, Household, Other), Drug Type (Penicillins, Sulfonami...
$ 3750
Legal Marijuana Comprehensive Study by Type (Indoor, Greenhouse), Application (Chronic Pain, Mental Disorders, Cancer, Others), End-Users (Healthcare Industry, Recreational Industry, Others) Players ...
$ 3500
Veterinary Drugs Comprehensive Study by Type (Antibiotics, Non-Steroidal Anti-Inflammatories, Steroids, Opioid Pain Relievers, Anti-Parasitics, Behavior-Modifying Drugs and Sedatives, Hormones, Chemo...
$ 3750
Divalproex Sodium Comprehensive Study by Type (Tablet, Capsule, Others), Application (Epilepsy, Manic-Depressive Illness, Migraine Prophylaxis, Other), Sales Channel (Hospital Pharmacies, Online Phar...
$ 3450
Albumin Comprehensive Study by Type (Human Serum Albumin, Recombinant Albumin), Application (Drug Formulation, Vaccines, Medical Device Coating, Culture Medium & Stabilizer, Diagnostics, In Vitro Fer...
$ 3450
Acne Drugs Comprehensive Study by Mode of Administration (Oral, Topical, Injectable), Therapeutic Class (Retinoid, Antibiotic, Hormonal Agent, Combination, Others), Age Group (0-10 years, 11-16 years...
$ 3450